Maze Therapeutics (MAZE) Shares Outstanding (Weighted Average) (2024 - 2026)

Maze Therapeutics has disclosed Shares Outstanding (Weighted Average) across 3 years of filings, most recently posting $53.9 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $53.9 million, up 88.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.9 million (up 88.26% YoY), and the FY2025 annual result was $43.0 million, up 1693.59% from the prior year.
• Shares Outstanding (Weighted Average) came in at $53.9 million for Q1 2026 at Maze Therapeutics, up from $43.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $53.9 million in Q1 2026 to a low of $2.3 million in Q1 2024.
• The 3-year median for Shares Outstanding (Weighted Average) is $28.6 million (2025), against an average of $24.1 million.
• Across the five-year window, Shares Outstanding (Weighted Average) soared 1820.19% in 2025 and soared 88.26% in 2026, its largest moves.
• Maze Therapeutics' Shares Outstanding (Weighted Average) stood at $2.4 million in 2024, then surged by 1693.59% to $43.0 million in 2025, then climbed by 25.41% to $53.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $53.9 million (Q1 2026), $43.0 million (Q4 2025), and $45.8 million (Q3 2025), per Business Quant data.